Breaking News from ADA 2019


This page was last updated at 3:30 pm PT on June 11, 2019.

Editor’s Note: This article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on Twitter at #ADA2019

Tuesday, June 11

Monday, June 10

Sunday, June 9

Saturday, June 8

Friday, June 7

Thursday, June 6 

  • Abbott announced that the FreeStyle LibreLink app for Android users is now available in the U.S. The app was previously only available on iOS.
  • Xeris Pharmaceuticals announced a PDUFA date extension for the Gvoke™ HypoPen. Instead of June 10, the Gvoke™ will receive an FDA decision by September 10, 2019.
  • Senseonics announced that the Eversense CGM system received FDA approval for a non-adjunctive indication. Patients may have already been relying on Eversense for dosing, but this FDA approval marks a step towards one day using Eversense in a closed-loop system.
  • Ahead of the official start of ADA 2019, the American Diabetes Association made important changes to its 2019 Standards of Care for diabetic nephropathy based on the results of the CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial. Results showed the risk of end-stage renal disease, doubling of serum creatinine, and death from renal causes lowered by 34 percent after treatment with SGL2 inhibitor canagliflozin. The ADA’s updates for clinicians include changes to the frequency of assessing urinary albumin and estimated glomerular filtration rate; the time at which T2D patients with nephropathy should be treated with an SGLT2 inhibitor; the use of GLP-1s to reduce the risk of cardiovascular events, and removal of previous recommendations for microvascular complications and foot care.

Click here for complete coverage of ADA 2019 from Beyond Type 2.

WRITTEN BY Beyond Type 2 Editorial Team, POSTED 06/04/19, UPDATED 10/04/22

This piece was authored collaboratively by the Beyond Type 2 Editorial Team.